Hong Kong Pharmaceutical & Biotech Tax — Expert Advisory

Under s.16B of the IRO, qualifying R&D expenditure attracts a deduction of 300% for the first HKD 2M of qualifying in-house R&D expenditure, and 200% for the remainder. For payments to approved R&D centres, a 100% deduction applies. This is one of Hong Kong's most powerful tax incentives for technology and life sciences companies.

Qualifying expenditure includes: staff costs for employees directly engaged in R&D; consumables, reagents, and materials used in R&D; costs of acquiring plant & machinery for R&D (if not otherwise claimed as capital allowances); and fees paid to approved research institutions. The R&D activities must be of a scientific or technology nature and must relate to the company's trade.

Yes, from 2023 Hong Kong introduced preferential tax treatment for qualifying IP income under the Refined FSIE regime and IP regime. Qualifying patent income can benefit from a reduced effective tax rate. The qualifying IP must be created through substantial R&D activities in HK. Pharmaceutical patents, drug formulations, and medical device patents can potentially qualify.

Government grants received for R&D activities (e.g., from InnoHK, ITC, or HKSAR government) are generally taxable income if they are revenue in nature and relate to assessable profits. Capital grants for equipment purchase may need to be deducted from the cost of the asset for capital allowance purposes. Overseas grants require case-by-case analysis.

Phase I, II, and III clinical trials conducted in Hong Kong can potentially qualify as R&D expenditure under s.16B if they involve systematic investigation aimed at advancing scientific or technical knowledge. The costs must be incurred in HK and directly related to the R&D programme. Clinical trial management fees paid to approved research institutions may also qualify. Detailed record-keeping of trial protocols and expenditure is essential.